WANBURY
Back to Income Statement
|
WANBURY Last 5 Year Revenue History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Net Sales | ₹600 Cr | ₹578 Cr | ₹500 Cr | ₹511 Cr | ₹393 Cr |
What is the latest Revenue of WANBURY ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹600 Cr |
| Mar2024 | ₹578 Cr |
| Mar2023 | ₹500 Cr |
| Mar2022 | ₹511 Cr |
| Mar2021 | ₹393 Cr |
How is Revenue of WANBURY Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹600 Cr | 3.77 | |
| Mar2024 | ₹578 Cr | 15.63 | |
| Mar2023 | ₹500 Cr | -2.26 | |
| Mar2022 | ₹511 Cr | 30.23 | |
| Mar2021 | ₹393 Cr | - | |
Compare Revenue of peers of WANBURY
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| WANBURY | ₹651.7 Cr | -0.2% | -18.3% | -22.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹420,831.0 Cr | -0.4% | -6.1% | 5.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹242,074.0 Cr | 0.9% | -3.3% | 39.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹175,355.0 Cr | 0.1% | -7.2% | 28.2% | Stock Analytics | |
| CIPLA | ₹107,439.0 Cr | -0.3% | -4% | -15.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,417.0 Cr | 1.5% | 3.1% | 0.4% | Stock Analytics | |
WANBURY Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| WANBURY | -0.2% |
-18.3% |
-22.8% |
| SENSEX | 0.6% |
-1.4% |
-10.7% |
You may also like the below Video Courses